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Summary: Nasal carriage of Staphylococcus aureus is a risk factor for the 
development of infections caused by S. aureus in haemodialysis patients. 
This study compared the incidence of bacteraemia caused by S. aureus 
during 6 months of use of nasal 2% calcium mupirocin (‘Nasal Bactroban’) 3- 
times a week for nasal carriers with the incidence observed previously in the 
same dialysis unit without the use of mupirocin. Nasal mupirocin led to the 
total eradication of nasal carriage of S. aureus, a 4.26-fold reduction in the 
incidence of S. aureus bacteraemia, and a substantial cost saving. After a 
cumulative experience of nasal mupirocin in haemodialysis patients of more 
than 43 patient-years, the development of mupirocin resistance was not 
observed. 
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Introduction 
Infection is known to be the principal cause of morbidity and the second 
commonest cause of mortality in patients with chronic renal failure, treated 
by maintenance haemodialysis.‘s2 Staphylococcus aureus is the 
microorganism most commonly implicated in these infections.2’3 Nasal 
carriage is considered to play an important role in the pathogenesis of 
infections caused by S. aureus in patients on haemodialysis4 or on 
continuous ambulatory peritoneal dialysis.5 Elimination of staphylococcal 
nasal carriage, either by oral rifampicin combined with nasal bacitracin’ or 
by nasal calcium mupirocin,3 has been reported to reduce the rate of 
staphylococcal infection in haemodialysis patients. 
The present study compares the incidence of bacteraemia caused by S. 
aureus in a haemodialysis unit before and after the use of nasal mupirocin for 
the elimination of nasal carriage. Particular emphasis is given to the analysis 
of cost effectiveness. 
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Patients and methods 
Between September 1989 and the end of March 1990, all patients on 
maintenance haemodialysis in a haemodialysis unit were screened for nasal 
carriage of S. aureus. They were considered carriers if two nasal swabs taken 
one week apart were positive for S. aureus. All carriers, after giving their 
consent, were prescribed 2% calcium mupirocin (‘Nasal Bactroban’). The 
ointment was applied to the anterior nares three times daily for the first five 
days and subsequently at the end of each haemodialysis session, i.e. three 
times weekly. The methods for sampling the nares and for the isolation, 
identification, minimum inhibitory concentration (MIC) determination, 
and phage typing of S. aureus were as previously reported.6 Repeat swabs 
were obtained from both anterior nares at the end of the third and the sixth 
month of the trial. 
The patients were followed prospectively for the development of 
bacteraemia caused by S. aureus. When a patient presented with fever 
> 38”C, with or without signs of infection, three pairs of blood cultures were 
collected using a standard aseptic technique. Blood culture isolates of S. 
aureus were considered as relevant if grown from more than two of the six 
culture bottles. The incidence of S. aureus bacteraemia in the total 
haemodialysis population, during the six months in which nasal carriers 
were treated with mupirocin, was compared with the incidence of S. aureus 
bacteraemia during a 2-year period when mupirocin prophylaxis had not 
been used (which had been previously prospectively assessed3). In order to 
allow comparison between the two study periods, the episodes of S. aureus 
bacteraemia that occurred within the first month of haemodialysis, excluded 
from the previous 2-year incidence study,6 were included in the present 
comparison. Of the 106 patients in the present trial, 71 (67%) treated with 
mupirocin had also been assessed for bacteraemia caused by S. aureus in the 
previous pre-mupirocin trial. 
The combined costs of prophylaxis and treatment of S. aureus 
bacteraemia were compared for the two study periods, with and without 
mupirocin prophylaxis. In the absence of mupirocin prophylaxis, the costs 
assessed were those of the treatment of S. aureus bacteraemia, namely the 
cost of hospitalization, diagnostic investigation and drug treatment. For the 
6 months of mupirocin prophylaxis, the costs included, in addition, the cost 
of nasal cultures plus the cost of 2% calcium mupirocin ointment (which is 
commercially available in the UK). The costs, in US dollars, were 
expressed per patient-year at risk. 
Statistical analysis 
The characteristics of the patients in the two study periods were compared 
by contingency table analysis. The incidence of bacteraemia caused by S. 
aureus was compared by the Fisher’s exact test. 
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43 
During the 6 months of the study, 106 patients in our unit were on 
maintenance haemodialysis, with a total follow-up of 44.1 patient-years. 
Their characteristics are shown in Table I. There was no significant 
difference between the two patient groups concerning the age distribution 
and the fraction of patients with diabetes mellitus, with iron overload 
(defined by a serum ferritin > lmg 1-l) or with dialysis through a central 
venous catheter. Of the 106 patients, 43 (41%)’ were nasal carriers of S. 
uuwus which was always sensitive to mupirocin. These 43 nasal carriers 
received mupirocin nasal ointment prophylactically for a total follow-up of 
16.75 patient-years: 29 patients were followed for 6 months, 8 for 224 
months and 6 for less than 2 months. A total of 60 nasal cultures was taken 
from 31 patients 3 and 6 months after the start of the 6 months study of 
mupirocin prophylaxis; none of the swabs yielded S. aureus. 
There was only one episode of S. aureus bacteraemia recorded during the 
44.1 patient-years of follow-up, an incidence of 0.0227 per patient-year at 
risk. The source of S. aureu~ for the single bacteraemic episode could not be 
identified, and a nasal culture taken at the time of bacteraemia, prior to 
antibiotic therapy, failed to yield S. uureus. The S. aweus isolated from the 
blood was sensitive to mupirocin and was of the same phage type as the 
strain isolated from the patient’s nose prior to mupirocin use. The 2% 
calcium mupirocin ointment was well tolerated in all patients. 
Table I. Patient characteristics and incidence of S. aureus bacteraemia with, and without, 
mupirocin 
Patient characteristics Without mupirocin* 
(N= 158) 
With mupirocin 
to carriers 
(N= 106) 
Percentage of patients aged 
<65 years 
> 65 years 
62% 
38% 
No. (%) with nasal carriage of S. aureus NT 
No. of patient-years of follow up 1858 
Percentage of patient-years with: 
diabetes mellitus 
serum ferritin < 1 mg 1-l 
> 1 mg 1-l 
central venous dialysis catheter 
No. of bacteraemias caused by S. aureus 
Incidence of S. aureus bacteraemia per 
patient-year 
10.9% 
81.0% 
19.0% 
3.2% 
18 
0.0969 
60.4% 
39.6% 
43 (40.5%) 
44.1 
13.8% 
87.5% 
12.5% 
5.5% 
1 
0.0227t 
* Results previously reported by Boelaert et al. 
NT: Not tested. 
t P=O.OS (Fisher’s exact test). 
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In the absence of mupirocin prophylaxis there were 18 bacteraemias 
caused by S. aureu~ during 185.8 patient-years, an incidence of O-0969 per 
patient-year at risk. The incidence of S. aureus bacteraemia during 
mupirocin prophylaxis was reduced 4*26-fold, when compared to the 
previous 2 years when mupirocin was not used (P= 0.08). 
The cost of treating and/or preventing S. aureus bacteraemia was 
compared for the two study periods: without and with mupirocin 
prophylaxis. In our previous study when nasal mupirocin was not used, the 
cost for the treatment of an episode of S. aureu~ bacteraemia ranged from 
$763 to $87 229 (mean= $9249; median = $3429). The mean cost per 
patient-year at risk for the treatment of S. aureus bacteraemia was $896. 
During mupirocin prophylaxis, the calculated mean cost for the treatment 
of S. aureus bacteraemia per patient-year at risk was $210. The cost of 
monitoring nasal cultures every 3 months was $32 per patient-year and the 
eradication of nasal staphylococcal carriage by mupirocin in c.40% of the 
haemodialysis population was $60 x 0.4, or $24 per patient-year. Thus, 
when using mupirocin prophylaxis, the average total cost was $266. This 
cost is only 30% of the cost of treating S. aweus bacteraemia in the period 
prior to using mupirocin prophylaxis. 
Discussion 
We previously reported the results of a double-blind, placebo-controlled 
trial which showed that 2% calcium mupirocin nasal ointment was effective 
in eradicating nasal carriage of S. aureus and in decreasing the rate of S. 
aureus infections in patients on maintenance haemodialysis.6 A subsequent 
study in the same patient population showed that some weeks or months 
after a single S-day course of nasal mupirocin, S. aureus tended to recolonize 
the nares, while staphylococcal nasal recolonization did not occur when 
nasal mupirocin application was continued thrice weekly, i.e. after each 
haemodialysis. ’ Therefore, nasal mupirocin was applied 3 times per week 
throughout the present study, after an initial S-day-course. Eradication of 
nasal S. aureus and the absence of recolonization during mupirocin 
prophylaxis in 43 carriers in the present study confirms our previous 
results. 
Staphylococcus aureus infections in haemodialysis patients frequently lead 
to bloodstream invasion with potential complications, such as S. aureus 
endocarditis, osteomyelitis or pulmonary infarction. The incidence of S. 
aureus bacteraemia during the period of mupirocin use was compared with 
that previously observed without mupirocin in a comparable dialysis 
population, Risk factors for infection, such as diabetes mellitus,’ 
transfusional iron overload3 and dialysis through a central venous catheter* 
were not significantly different between the two patient populations. The 
present study shows that mupirocin prophylaxis in nasal carriers decreases 
the incidence of S. uureus bacteraemia 4*26-fold, as compared with the 
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incidence observed in haemodialysis patients in the pre-mupirocin era. The 
difference was not statistically significant in the Fisher’s exact test 
(P= O-08), but this may reflect the much shorter period of observation in the 
mupirocin trial and a more prolonged study is required. However, even if 
not statistically significant, a 4+26-fold decrease in the incidence of S. aureu~ 
bacteraemia is clinically relevant. 
The median cost for the treatment of one episode of S. aUreUS bacteraemia 
in the pre-mupirocin era was $3429. However, one of these episodes of 
infection was complicated by endocarditis, requiring the insertion of a 
prosthetic valve and prolonged hospitalization, which accounts for the mean 
cost of $9249.6 Expressed per patient-year at risk, the cost for the treatment 
of S. UZU~US bacteraemia was $986. This contrasts to the calculated cost of 
$266 when mupirocin prophylaxis is applied. The use of mupirocin 
prophylaxis in haemodialysis patients with staphylococcal nasal carriage is 
therefore cost effective, as it leads both to a >4-fold reduction in the 
incidence of S. aureus bacteraemia, and to substantial saving.’ 
Several reports have mentioned a small number of cases where mupirocin 
resistance existed naturally or was induced, either experimentally or during 
long-term mupirocin therapy. This problem has recently been reviewed.” 
During a cumulative experience of more than 43 patient-years of nasal 
application of mupirocin 3-times per week in haemodialysis patients, we 
have not observed emergence of mupirocin resistance in our unit. However, 
caution is warranted. A lower frequency of mupirocin application might be 
as effective as our thrice weekly regimen and might reduce the risk of the 
development of resistance. We are presently studying such a once-weekly 
regimen. 
The authors wish to thank Mr G. Tormans and Mr J. Van Maele for their help in the cost 
analysis and statistical analysis, respectively. 
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